Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin

Sharyn N. Lewin, David G. Mutch, Bradford P. Whitcomb, Helen Liapis, Thomas J. Herzog

Research output: Contribution to journalArticle

28 Scopus citations

Abstract

Background. Hemolytic uremic syndrome (HUS) is a rare coagulation disorder characterized by microangiopathic hemolytic anemia, thrombocytopenia and acute uremia. Reports have described this fatal syndrome in association with cytotoxic agents. To our knowledge, no case reports of HUS in ovarian cancer patients receiving treatment with combination gemcitabine and pegylated liposomal doxorubicin (PLD) have been reported. Case Reports. Three patients with recurrent ovarian carcinoma each developed profound hypertension and peripheral edema while receiving combination gemcitabine and PLD. The first patient had rapid hemolysis, thrombocytopenia, renal failure and respiratory distress. The other patients experienced slowly progressive renal failure and mild hematologic abnormalities. Two of the three patients had favorable outcomes. Conclusion. The reported incidence of gemcitabine-induced HUS is rare. Clinicians should suspect HUS if blood pressure elevation or peripheral edema develop.

Original languageEnglish
Pages (from-to)228-233
Number of pages6
JournalGynecologic oncology
Volume97
Issue number1
DOIs
StatePublished - Apr 2005

Fingerprint Dive into the research topics of 'Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin'. Together they form a unique fingerprint.

  • Cite this